Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.445 EUR | -0.82% | +1.21% | -18.00% |
Apr. 25 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 | |
Apr. 24 | Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.00% | 274M | - | ||
+0.67% | 42.19B | B | ||
+44.30% | 40.15B | A | ||
-6.20% | 28.31B | C | ||
+6.55% | 24.63B | B- | ||
-21.66% | 18.2B | B | ||
+29.96% | 12.01B | C+ | ||
-1.57% | 11.76B | C+ | ||
+16.03% | 10.4B | B+ | ||
-4.80% | 9.94B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NANO Stock
- Ratings Nanobiotix